Moving beyond targeting CD38, elotuzumab is another monoclonal antibody approved for MM instead directed against Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) (37, 38). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.